Skip to main content

Improving patient health outcomes and optimisation of care through the development of a cardiometabolic medicines optimisation clinic and innovative pathways with Leeds Teaching Hospitals NHS Trust Joint Working Project Executive Summary

Implementation of a specific cardiometabolic medicines optimisation pathway and treatment protocol, including the design and set up post-acute event clinics for eligible patients with Type 2 Diabetes (T2D).

A Joint Working project between Leeds Teaching Hospitals NHS Trust (LTHT) and Boehringer Ingelheim Ltd (BIL).

Elevated levels of blood glucose, and diabetes itself, lead to increased risk of CVD through multiple mechanisms, including insulin resistance, inflammation, endothelial dysfunction, and the toxic effects of glucose on microvasculature. In addition, elevated blood glucose levels are associated with a common set of other underlying metabolic risk factors, including hypertension, dyslipidaemia, and central obesity. Risk is also strongly affected by smoking and by low levels of physical activity. This wide range of risk factors is accompanied by numerous opportunities to reduce risk.1

LTHT and BIL have designed this Joint Working project to implement a specific cardiometabolic medicines optimisation pathway and treatment protocol, including the design and set up of post-acute event clinics for eligible patients with T2D, which aims to:

  • Optimise and reduce the cardiovascular risk factors amongst patients with T2D and cardiovascular disease.

  • Provide better patient management, including education and self-management.

  • Enable patients discharged from clinic to have better diabetes control through improved medication adherence and medication optimisation by providing strategies to address a number of factors that may impact an individuals’ adherence to their medications.

  • Enable timely interventions to reduce the need for further treatment escalation and reduced hospital stays.

  • Offer patients with T2D following an MI, the use of guideline-directed cardiometabolic treatments.

The Joint Working project seeks to optimise and reduce the cardiovascular risk factors amongst patients with T2D and cardiovascular disease through supporting the development of cardiometabolic clinics for post-MI patients, scheduled for 6-8 weeks after the event of an MI.

The pilot started in November 2020 and is anticipated to run until February 2023.

Boehringer Ingelheim Limited is pleased to collaborate with Leeds Teaching Hospital NHS Trust and explore the challenges and support needed to design and deliver an innovative, high-quality model of care in medicines optimisation for a high risk cohort of patients, with a leading UK Teaching hospital.

Reference

1. IDF Diabetes Atlas - 9th Edition. Available at: https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf

 


NP-GB-105044   September 2024